Forum Discussion on a New Injectable GLP-1 Drug's Phase 2b Results

The thread reviews phase 2b data showing 12.3 percent weight loss at 28 weeks for an injectable GLP-1. Participants note the once-monthly dosing as a potential edge but expect most people to prefer orals. They highlight that insurance coverage will hinge on final cost, with niches still existing for injections even if daily pills become common.

• 12.3 percent weight loss reported at 28 weeks
• Once-monthly injection format highlighted as novel
• Most users expected to choose pills over any injection
• Cost to insurers seen as the decisive factor for broad adoption
• Smaller patient groups still use infrequent injections for other therapies

Whether the monthly schedule offers enough convenience to offset the general preference for oral options.

Whether the drug can reach a cost low enough for Medicare, Medicaid, and private plans to cover it widely.

Nothing here is advice.